A new CRISPR-based strategy turns cancer cells' own mutant transcripts against them, opening a potential route to one of oncology's most stubborn...
Alpha-1 antitrypsin deficiency (AATD) has turned into the most crowded proving ground in genetic medicine, with five editing companies reporting fresh...
Intellia Therapeutics has initiated a rolling biologics license application (BLA) with the U.S. Food and Drug Administration for lonvoguran ziclumeran...
One or two years ago, if you had proposed lipid nanoparticles (LNPs) as an RNA delivery system for muscle diseases, you would likely have been met...
Engineered virus-like particles (eVLPs) are emerging as a distinct delivery platform for CRISPR-Cas ribonucleoprotein (RNP) complexes, combining the...
The US FDA has issued a Study May Proceed notification for PBGENE-DMD, Precision BioSciences' investigational in vivo gene-editing therapy for...
On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based...
iECURE's ECUR-506 has secured both the US FDA Regenerative Medicine Advanced Therapy designation and a UK Innovation Passport, positioning the...
